Raphanaud D, Borensztejn M, Dupeyron J P, Guyon F
Ther Drug Monit. 1986;8(3):365-7. doi: 10.1097/00007691-198609000-00023.
Procainamide is used in antiarrhythmic therapy, and the need to monitor the drug concentration as well as its major plasma metabolite, N-acetyl-procainamide, is well established. An assay designed for the routine clinical therapeutic drug monitoring laboratory has been developed. A 0.5-ml aliquot of blood plasma is treated with 0.1 ml of internal standard solution, and the mixture is alkalinized. The drug, its metabolite, and the internal standard, N-propionyl procainamide are extracted with methylene chloride. After evaporation to dryness and addition of 0.3 ml of mobile phase, a volume of 0.1 ml is injected onto a liquid chromatograph equipped with spectrofluorimetric detection, which has a better specificity than UV absorptiometric detection. The between-day coefficient of variation was 3.5% for procainamide and 5% for N-acetylprocainamide. The sensitivity of this technique permits detection of 0.1 micrograms/ml of procainamide and 0.25 micrograms/ml of N-acetylprocainamide. Several drugs that are often present in patients receiving procainamide were shown not to interfere.
普鲁卡因胺用于抗心律失常治疗，监测其药物浓度及其主要血浆代谢物N - 乙酰普鲁卡因胺的必要性已得到充分证实。现已开发出一种适用于常规临床治疗药物监测实验室的检测方法。取0.5 ml血浆等分试样，加入0.1 ml内标溶液进行处理，然后将混合物碱化。药物、其代谢物以及内标N - 丙酰普鲁卡因胺用二氯甲烷萃取。蒸发至干并加入0.3 ml流动相后，取0.1 ml注入配备荧光检测的液相色谱仪，该检测比紫外吸收检测具有更好的特异性。普鲁卡因胺的日间变异系数为3.5%，N - 乙酰普鲁卡因胺为5%。该技术的灵敏度可检测到0.1微克/毫升的普鲁卡因胺和0.25微克/毫升的N - 乙酰普鲁卡因胺。结果表明，接受普鲁卡因胺治疗的患者体内常存在的几种药物不会产生干扰。
